ATLANTA, GA--(MARKET WIRE)--Jul 20, 2006 -- AtheroGenics, Inc. (NASDAQ:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported financial results for the second quarter and six months ended June 30, 2006. During the second quarter, AtheroGenics revenue totaled $6.3 million. For the six months ended June 30, 2006, revenue totaled $10.4 million. The revenue recorded in both periods is related to the Company’s collaboration agreement with AstraZeneca and reflects the amortization of the $50 million up-front license fee received in February 2006.
